Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ESODOC is an injectable formulation of esomeprazole, a proton pump inhibitor (PPI) developed and marketed by Docventures Pharmaceuticals in India. As the S-isomer of omeprazole, esomeprazole works by irreversibly inhibiting the H+/K+-ATPase enzyme system (the proton pump) in the gastric parietal cells, thereby suppressing the final step of gastric acid secretion. This injectable form is primarily indicated for the short-term treatment of gastroesophageal reflux disease (GERD) with erosive esophagitis in patients who are unable to take oral medication, as well as for the treatment of pathological hypersecretory conditions like Zollinger-Ellison syndrome and the prevention of gastric ulcers associated with continuous NSAID therapy.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ESODOC.